Companies Related to "Effects of E-cigarettes (ECIGs) on Pulmonary Inflammation and Behavior in HIV Infected Smokers" [Most Relevant Company Matches] RSS

10:46 EST 18th December 2018 | BioPortfolio

Here are the most relevant search results for "Effects of E-cigarettes (ECIGs) on Pulmonary Inflammation and Behavior in HIV Infected Smokers" found in our extensive corporate database of over 50,000 company records.

Showing "Effects cigarettes ECIGs Pulmonary Inflammation Behavior Infected Smokers" Companies 1–25 of 914

Extremely Relevant

Electronic Cigarettes International Group, Ltd.

Electronic Cigarettes International Group (ECIG) is dedicated to providing a compelling alternative to traditional cigarettes for the more than 1 billion current smokers around the world. ECIG offers consumers a full product portfolio that incorporates product quality and the latest technology. The Company’s website is


22nd Century Limited, LLC

Founded in 1998, 22nd Century is a plant biotechnology company whose proprietary technology allows for the level of nicotine (and other nicotinic alkaloids) in the tobacco plant to be decreased or increased through genetic engineering and breeding. The company owns exclusive rights to 97 issued patents in 79 countries where at least 75% of the world’s...

Inverseon, Inc.

Inverseon's product development programs target significant unmet medical needs and major market opportunities in chronic pulmonary diseases such as asthma, COPD and pulmonary hypertension. Inverseon was founded based on the original work of Prof. Richard Bond of the University of Houston. Professor Bond termed the effects “Paradoxical Pharmacologyâ...

22nd Century Group, Inc.

Founded in 1998, 22nd Century Limited, LLC (22nd Century) is a plant biotechnology company whose proprietary technology allows for the level of nicotine (and other nicotinic alkaloids) in the tobacco plant to be decreased or increased through genetic engineering and breeding. The company owns or exclusively controls 98 issued patents in 79 countries where ...

Ballantyne Brands, LLC

Electronic cigarettes are alternatives for traditional tobacco. Ballantyne Brands distributes its electronic cigarettes to thousands of retail outlets across the country. NEO™ and Mistic™ electronic cigarettes, commonly called e-cigs, are available in both traditional tobacco and menthol flavors. They also offer both rechargeable and non-recharge...

Electronic Cigarette Industry Group

The Electronic Cigarette Industry Group, Inc. (ECIG) is a non-profit association of consumers, manufacturers, importers and distributors of electronic cigarettes. ECIG advocates for reasonable regulation of electronic cigarettes. ECIG supports strengthening laws to keep electronic cigarettes out of the hands of children. For more information, please refer ...


GN Operations, Inc. wants to create a smoke free environment by offering options for smokers to "smoke" nicotine without the fire, flame, tobacco, tar, carbon monoxide, ash, smell, and the variety of chemicals found in traditional tobacco cigarettes. However, we are dedicated to making certain our customers receive the highest quality ingredients the electronic cigarette (e-cig) world has to offe...

The Behavior Analyst Certification Board®, Inc

The Behavior Analyst Certification Board®, Inc. (BACB®) is a nonprofit 501(c)(3) corporation established to meet professional credentialing needs identified by behavior analysts, government, and consumers of behavior analysis services.


Mistic® electronic cigarettes is a conscious-minded brand of high-quality vapor products, primarily sold through brick-and-mortar retail channels under the direction of its parent company, Ballantyne Brands. Mistic electronic cigarettes and vapor products are sold in approximately 40,000 retail outlets across the country, including Walmart, Walmart ...

Synedgen Inc.

Synedgen Inc. is developing a new class of drugs with the ability to suppress inflammation, reduce infection and improve healing in the gastrointestinal tract and pulmonary tree and to reduce damage and inflammation due to chemical, radiological or physical damage using the science of glycomics - the study of complex sugar structure and function. Synedgen ...

Pulmonary Hypertension Association (PHA)

Headquartered in Silver Spring, Md., PHA is the country’s leading organization connecting pulmonary hypertension patients, families, and medical professionals. Its mission is to find ways to prevent and cure pulmonary hypertension and provide hope for the community through support, education, advocacy and awareness. PHA provides free access to informa...

Smokefree Innotec, Inc.

Smokefree Innotec, Inc. is in the business of designing, developing, manufacturing and marketing hi-tech, nicotine and non-nicotine cigarette-like delivery devices which are completely smoke and vapor-free and tobacco-free. Smokefree Innotec’s products are designed to protect the non-smoker from second hand smoke and all its effects while providing th...

e-Nicotine Technology (eNT)

eNT is a healthcare company committed to reducing the harms associated with combustible tobacco products. eNT is developing the next generation of state-of-the-art electronic nicotine delivery products that quickly and dramatically reduce smoking urge while using 40-70% less nicotine than cigarettes or existing e-cigarettes. eNT’s products del...

VIDA Diagnostics, Inc.

VIDA Diagnostics is a leader in quantitative pulmonary image analysis for the diagnosis and treatment of pulmonary diseases. VIDA Diagnostics develops and commercializes pulmonary applications, establishing quantitative pulmonary imaging in routine clinical practice. VIDA is an established leader in quantitative lung analysis for COPD, emphysema and asthma, establishing objective, quantitative me...

Sagene Pharmaceuticals

Sagene Pharmaceuticals is a biopharmaceutical company developing novel applications for combinations of FDA-approved drugs to treat diseases associated with aging. Sagene has shown that selective MAO-B inhibitors, specifically selegiline (l-deprenyl), can reduce side effects and enhance efficacy in combination with current treatments for erectile dy...

E Cigarettes National

World of E Cigarettes

E-Cigarettes National


Synspira is developing a new class of inhalable glycopolymer-based therapeutics that disrupt mucus accumulation and biofilm invasion, which are key drivers of pulmonary diseases including cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and pneumonia. Synspira has an exclusive license from Synedgen to the Glycomics Technology Platform fo...

Colby Pharmaceutical Company

Colby is a privately held company based in Madison, WI and San Jose, CA. Colby is developing new oral small molecule signal transduction modulator drugs and immune modulator biopharmaceuticals for cancer, chronic inflammation, pain, infectious diseases, and neurodegenerative diseases. Colby’s lead small molecule candidates have unique mechanisms of ac...

Coalition for Pulmonary Fibrosis

Pulmonary Fibrosis (PF) is a lung disorder characterized by a progressive scarring - known as fibrosis -- and deterioration of the lungs, which slowly robs its victims of their ability to breathe. Approximately 128,000 Americans suffer from PF, and there is currently no known cause or cure. An estimated 48,000 new cases are diagnosed each year. PF is difficult to diagnose and an estimated two-thir...

Arizona Smokers' Helpline

FluGen Inc.

FluGen, Inc. is a clinical stage vaccine company focused on improving the breadth and effectiveness of influenza vaccines. The Company’s technology comes from the laboratory of Dr. Yoshihiro Kawaoka at the University of Wisconsin, Madison. It’s lead product candidate, RedeeFlu™ is a universal flu vaccine which is based on the knowledge that a ...

Habit Changer

Habit Changer is a set of online programs that is recognized by third party experts and designed to help participants, from all walks of life—different age groups, incomes and lifestyles—recognize the underlying behavior of their bad habits and work to replace them with good behavior.

The Pulmonary Fibrosis Foundation

The Pulmonary Fibrosis Foundation is 501©(3) organization, whose mission is to find a cure for idiopathic pulmonary fibrosis (IPF) by funding research, advocating for IPF issues, promoting disease awareness, and providing a compassionate environment for supporting patients and their loved ones. We achieve these goals by promoting new research through increased funding; by representing the needs o...

More From BioPortfolio on "Effects of E-cigarettes (ECIGs) on Pulmonary Inflammation and Behavior in HIV Infected Smokers"

Quick Search


Corporate Database Quicklinks